Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Ltd. / URL Pharma, Inc.

2012 · Acquisition/Merger · $800M · Complete

Announcement Sentiment

Positive

Takeda America Holdings acquired URL Pharma for $800M upfront plus performance-based contingent earn-outs. Brought Colcrys (only FDA-approved single-ingredient oral colchicine; FY2011 net sales >$430M) into Takeda's gout franchise alongside Uloric. URL's generic business divested to Sun Pharma.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Accretive

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Apr 11, 2012
Closed Jun 04, 2012
Deal value $800M
Deal type Acquisition/Merger
Therapeutic area Acute gout flares
Indications Acute gout flares
Key assets Colcrys (colchicine)
Mechanism Tubulin polymerization inhibitor (anti-inflammatory)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals